These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20510539)

  • 21. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
    Geyer JR; Stewart CF; Kocak M; Broniscer A; Phillips P; Douglas JG; Blaney SM; Packer RJ; Gururangan S; Banerjee A; Kieran MW; Kun LE; Gilbertson RJ; Boyett JM
    Eur J Cancer; 2010 Dec; 46(18):3287-93. PubMed ID: 20708924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of gefitinib in patients with metastatic melanoma.
    Patel SP; Kim KB; Papadopoulos NE; Hwu WJ; Hwu P; Prieto VG; Bar-Eli M; Zigler M; Dobroff A; Bronstein Y; Bassett RL; Vardeleon AG; Bedikian AY
    Melanoma Res; 2011 Aug; 21(4):357-63. PubMed ID: 21738104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
    de Groot JF; Gilbert MR; Aldape K; Hess KR; Hanna TA; Ictech S; Groves MD; Conrad C; Colman H; Puduvalli VK; Levin V; Yung WK
    J Neurooncol; 2008 Oct; 90(1):89-97. PubMed ID: 18581057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
    J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.
    Kumar R; Dubashi B; Kayal S; Lazzar SC; Barathi D; Kumar V
    Indian J Cancer; 2017; 54(1):188-192. PubMed ID: 29199688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
    Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
    Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
    Parker JJ; Dionne KR; Massarwa R; Klaassen M; Foreman NK; Niswander L; Canoll P; Kleinschmidt-Demasters BK; Waziri A
    Neuro Oncol; 2013 Aug; 15(8):1048-57. PubMed ID: 23749785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
    N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.
    Mikkelsen T; Lush R; Grossman SA; Carson KA; Fisher JD; Alavi JB; Rosenfeld S
    Invest New Drugs; 2007 Jun; 25(3):259-63. PubMed ID: 17080256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
    Lustig R; Mikkelsen T; Lesser G; Grossman S; Ye X; Desideri S; Fisher J; Wright J;
    Neuro Oncol; 2008 Dec; 10(6):1004-9. PubMed ID: 18725460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
    Kreisl TN; Lassman AB; Mischel PS; Rosen N; Scher HI; Teruya-Feldstein J; Shaffer D; Lis E; Abrey LE
    J Neurooncol; 2009 Mar; 92(1):99-105. PubMed ID: 19018475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
    Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
    Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
    Smith JS; Tachibana I; Passe SM; Huntley BK; Borell TJ; Iturria N; O'Fallon JR; Schaefer PL; Scheithauer BW; James CD; Buckner JC; Jenkins RB
    J Natl Cancer Inst; 2001 Aug; 93(16):1246-56. PubMed ID: 11504770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
    Hegi ME; Diserens AC; Bady P; Kamoshima Y; Kouwenhoven MC; Delorenzi M; Lambiv WL; Hamou MF; Matter MS; Koch A; Heppner FL; Yonekawa Y; Merlo A; Frei K; Mariani L; Hofer S
    Mol Cancer Ther; 2011 Jun; 10(6):1102-12. PubMed ID: 21471286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Park K; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Laurie SA; Tsai CM; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L
    Lancet Oncol; 2016 May; 17(5):577-89. PubMed ID: 27083334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
    Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
    Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
    Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
    J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.